- Recent Funding
- Investors
- BrightEdge - American Cancer Society
BrightEdge - American Cancer Society portfolio
BrightEdge - American Cancer Society has 4 portfolio companies on record at Recent Funding, with 2 investments in the last 12 months.
About this page
Its most recent investment on record is Cloverleaf Bio's $33M Seed round in September 2026, alongside 4BIO Capital, AbbVie, Eli Lilly and 3 others. By category, its portfolio leans toward Health and bio (4) and Data and analytics (1). It has co-invested with RA Capital Management, Forbion Capital Partners and Sozo Ventures, most often RA Capital Management (2 rounds).
What BrightEdge - American Cancer Society invests in
- Health and bio · 4 · 100%
- Data and analytics · 1 · 25%
- Education · 1 · 25%
BrightEdge - American Cancer Society recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Seed · $33M | 4BIO Capital (lead), AbbVie, Eli Lilly +3 | ||
| Series B+ · $220M | Venrock Healthcare Capital Partners (lead), Forbion Capital Partners, Fidelity +5 | ||
| Series B+ · $59M | Mindshift Capital, Bruker, Sozo Ventures (lead) +6 | ||
| Series B+ · $120M | Forbion Capital Partners (lead), Avego Management, RA Capital Management (lead) | ||
| Series A · $41M | Bruker, Broadway Angels, Sozo Ventures +4 |
How BrightEdge - American Cancer Society invests
BrightEdge - American Cancer Society portfolio companies
CCloverleaf Bio$33MSeed · Sep 2026
CCellCentric$220MSeries B+ · May 2026
MMercy BioAnalytics$59MSeries B+ · Sep 2025
CCellensbacker
| Company | Round with BrightEdge - American Cancer Society | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Seed · $33M | $33M | Sep 8, 2026 Seed |
Health and bio |
Series B+ · $220M | $340M | May 6, 2026 Series B+ |
Health and bio |
Series B+ · $59M | $100M | Sep 3, 2025 Series B+ |
Health and bio |
backer | undisclosed | — |
Most frequent co-investors
RRA Capital Management2 shared rounds · last May 6, 2026
FForbion Capital Partners2 shared rounds · last May 6, 2026
SSozo Ventures2 shared rounds · last Sep 3, 2025
NNovalis LifeSciences2 shared rounds · last Sep 3, 2025
LLabCorp2 shared rounds · last Sep 3, 2025
BBruker2 shared rounds · last Sep 3, 2025
IiSelect Fund2 shared rounds · last Sep 3, 2025
DDraper Associates1 shared round · last Sep 8, 2026
EEli Lilly1 shared round · last Sep 8, 2026
MMission BioCapital1 shared round · last Sep 8, 2026
BBoehringer Ingelheim Venture Fund1 shared round · last Sep 8, 2026
AAbbVie1 shared round · last Sep 8, 2026
Similar investors
AAble Partners4 companies · 1 deal in 12 mo
GGenoa Ventures5 companies · 4 deals in 12 mo
BBdc Thrive venture5 companies · 3 deals in 12 mo
BBpifrance Digital Venture5 companies · 3 deals in 12 mo
CCatalyst Health Ventures5 companies · 3 deals in 12 mo
NNPIF – Mercia Equity Finance5 companies · 3 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 5 rounds on Recent Funding that name BrightEdge - American Cancer Society. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists BrightEdge - American Cancer Society, which is a subset of its real portfolio. API: /api/v1/investors/brightedge-american-cancer-society (get a free API key). More: the most active VC firms and new venture capital funds.